


**Amendments to the Claims:**

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of  $C_{3-14}$  cycloalkyl, 3-14 membered heterocycloalkyl,  $C_{4-14}$  cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, heteroaryl; the cyclic moiety being optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, and alkylsulfonyl;

each of  $X^1$  and  $X^2$ , independently, is O or S;

$Y^1$  is  $-CH_2-$ ,  $-O-$ ,  $-S-$ ,  $-N(R^a)-$ ,  $-N(R^a)-C(O)-O-$ ,  $-O-C(O)-N(R^a)-$ ,  $-N(R^a)-C(O)N(R^b)-$ ,  $-O-C(O)-O-$ , or a bond; each of  $R^a$  and  $R^b$ , independently being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

$Y^2$  is  $CH_2$ ;

L is  $C_{4-8}$  a straight  $C_{3-12}$  hydrocarbon chain containing at least one double bond adjacent to  $Y^1$  or  $Y^2$ ; said unsaturated-hydrocarbon chain being optionally substituted with  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{4-14}$  alkoxy, hydroxyl, halo, amino, nitro,  $C_{3-5}$  cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl,  $C_{1-4}$  alkylcarbonyloxy,  $C_{1-4}$  alkylcarbonyl, or formyl,  $NH_2$ ,  $NH(C_{1-2} \text{ alkyl})$ , or  $N(C_{1-2} \text{ alkyl})_2$ , or  $N(C_{1-2} \text{ alkyl})_2$ ; and further being optionally interrupted by  $-O-$ ,  $-N(R^e)-$ ,  $-N(R^e)-C(O)-O-$ ,  $-O-C(O)-(R^e)-$ ,  $-N(R^e)-C(O)-N(R^d)-$ , or  $-O-C(O)-O-$ ; each of  $R^e$  and  $R^d$ , independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three

double bonds, said hydrocarbon chain is further substituted with  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{4-14}$  alkoxy, hydroxyl, halo, amino, nitro,  $C_{3-5}$  cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl,  $C_{4-14}$  alkylcarbonyloxy,  $C_{4-14}$  alkylcarbonyl, or formyl; and further provided that when L is  $C_{3-7}$  and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl,  $Y^1$  is not a bond or  $-CH_2-$ , and  $Y^2$  is  $-CH_2-$ ; provided that when L is  $C_4$  and A is  $C_{3-14}$  cycloalkyl then  $Y^1$  is not  $CH_2$ ; and further provided that when L is  $C_4$  containing two double bonds, and is  $\infty$  substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecanoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecanoic acid.

2. (Original) The compound of claim 1, wherein  $X^1$  is O.

3. (Original) The compound of claim 1, wherein  $X^2$  is O.

4. (Original) The compound of claim 1, where each of  $X^1$  and  $X^2$  is O.

5. (Previously Presented) The compound of claim 1, wherein  $Y^1$  is  $-CH_2-$ ,  $-O-$ ,  $-N(R^a)-$ , or a bond.

6. (Canceled)

7. (Original) The compound of claim 1, wherein L is an unsaturated  $C_{4-8}$  hydrocarbon containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being optionally substituted with  $C_{1-2}$  alkoxy, hydroxyl,  $-NH_2$ ,  $-NH(C_{1-2}$  alkyl), or  $-N(C_{1-2}$  alkyl) $_2$ , or  $-N(C_{1-2}$  alkyl) $_2$ .

8. (Original) The compound of claim 7, wherein the double bond is in trans configuration.

9-11. (Cancelled)

12. (Original) The compound of claim 1, wherein A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl.

13. (Previously Presented) The compound of claim 1, wherein A is phenyl optionally substituted with 1-3 substituents each of which is independently selected from the group consisting of alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl, and amino.


14-15. (Cancelled)

16. (Previously Presented) The compound of claim 13, wherein L is an unsaturated C<sub>4-8</sub> hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C<sub>1-2</sub> alkoxy, hydroxyl, -NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>.

17. (Previously Presented) The compound of claim 16, wherein X<sup>1</sup> is O; X<sup>2</sup> is O; and Y<sup>1</sup> is -CH<sub>2</sub>-, -O-, -N(R<sup>a</sup>)-, or a bond.

18-21. (Cancelled)

22. (Currently Amended) A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of aryl and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, hydroxylalkyl, or amino; each of X<sup>1</sup> and X<sup>2</sup>, independently, is O or S;

Y<sup>1</sup> is -CH<sub>2</sub>-, -O-, -S-, -N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-,

-O-C(O)-O-, or a bond; each of R<sup>a</sup> and R<sup>b</sup>, independently, being hydrogen, alkyl, hydroxylalkyl, or haloalkyl;

Y<sup>2</sup> is CH<sub>2</sub>;

L is an unsaturated C<sub>4-8</sub> a straight C<sub>3-12</sub> hydrocarbon chain containing at least one double bond adjacent to Y<sup>1</sup> or Y<sup>2</sup>; said unsaturated-hydrocarbon chain being optionally substituted with C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, nitro, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub> alkylcarbonyl, or formyl, -NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>, or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is substituted with C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, or amino; and further provided that when L is C<sub>3-7</sub>-C<sub>4-7</sub> and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y<sup>1</sup> is not a bond or CH<sub>2</sub>, and Y<sup>2</sup> is CH<sub>2</sub>;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecenoic acid.


23-24. (Cancelled)

25. (Original) The compound of claim 22, wherein L is an unsaturated C<sub>4-8</sub> hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C<sub>1-2</sub> alkoxy, hydroxyl, -NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>.

26. (Previously Presented) The compound of claim 25, where in X<sup>1</sup> is O; X<sup>2</sup> is O; and Y<sup>1</sup> is -CH<sub>2</sub>-, -O-, -N(R<sup>a</sup>)-, or a bond.

27-79. (Cancelled)

80. (Currently Amended) A pharmaceutical composition, comprising compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of  $C_{3-14}$  cycloalkyl, 3-14 membered heterocycloalkyl,  $C_{4-14}$  cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, and alkylsulfonyl; each of  $X^1$  and  $X^2$ , independently, is O or S;

$Y^1$  is  $-CH_2-$ ,  $-O-$ ,  $-S-$ ,  $-N(R^a)-$ ,  $-N(R^a)-C(O)-O-$ ,  $-O-C(O)-N(R^a)-$ ,  $-N(R^b)-C(O)-N(R^b)-$ ,  $-O-C(O)-O-$ , or a bond; each of  $R^a$  and  $R^b$  independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

$Y^2$  is  $CH_2$ ;

L is  $C_{4-8}$  ~~a straight  $C_{5-12}$~~  hydrocarbon chain containing at least one double bond adjacent to  $Y^1$  or  $Y^2$ ; said hydrocarbon unsaturated chain being optionally substituted with  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  alkoxy, hydroxyl, halo, amino, nitro,  $C_{3-5}$  cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl,  $C_{1-4}$  alkylcarbonyloxy,  $C_{1-4}$  alkyloxycarbonyl,  $C_{1-4}$  alkylcarbonyl, or formyl  $-NH(C_{1-2})_2$  alkyl), or  $-N(C_{1-2})_2$  alkyl), or  $-N(C_{1-2})_2$  alkyl), or eyane; and further being optionally interrupted by  $-O-$ ,  $-N(R^c)-$ ,  $-N(R^c)-C(O)-O-$ ,  $-O-C(O)-N(R^c)-$ ,  $-N(R^c)-C(O)-N(R^d)-$ , or  $-O-C(O)-O-$ ; each of  $R^c$  and  $R^d$ , independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when L is  $C_4$ , A is  $C_{3-14}$  cycloalkyl then  $Y^1$  is not  $CH_2$ ; and further provided that when L is  $C_4$  containing two double bonds, and is  $\omega$  substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is  $C_{3-7}$  and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl,  $Y^1$  is not a bond or  $CH_2$ , and  $Y^2$  is  $CH_2$ ;

or a salt thereof; and

a pharmaceutically acceptable carrier, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecanoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecanoic acid.

81. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein X<sup>1</sup> is O.

82. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein X<sup>2</sup> is O.

83. **(Previously Presented)** The pharmaceutical composition of claim 80, where each of X<sup>1</sup> and X<sup>2</sup> is O.

84. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein Y<sup>1</sup> is -CH<sub>2</sub>-  
-O-, -N(R<sup>8</sup>)-, or a bond.

85. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein L is an  
unsaturated C<sub>5-8</sub> hydrocarbon chain containing at least one double bond and no triple bond, said  
unsaturated hydrocarbon chain being optionally substituted with C<sub>1-2</sub> alkoxy, hydroxyl,  
-NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>, or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>.

86. **(Previously Presented)** The pharmaceutical composition of claim 85, wherein the double  
bond is in trans configuration.


87. **(Previously Presented)** The pharmaceutical composition of claim 80 wherein A is phenyl,  
naphthyl, indanyl, or tetrahydronaphthyl.

88. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein A is phenyl  
optionally substituted with 1-3 substituents, each of which is independently selected from the  
group consisting of alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl and amino.

89. (Previously Presented) The pharmaceutical composition of claim 80, wherein L is an unsaturated C<sub>5-8</sub> hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C<sub>1-2</sub> alkoxy, hydroxyl, -NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), or -N(C<sub>1-2</sub> alkyl)<sub>2</sub>.

90. (Previously Presented) The pharmaceutical composition of claim 89, wherein X<sup>1</sup> is O; X<sup>2</sup> is O; and Y<sup>1</sup> is -CH<sub>2</sub>-, -O-, -N(R<sup>a</sup>)-, or a bond.

91. (Currently Amended) A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C<sub>3-14</sub> cycloalkyl, 3-14 membered heterocycloalkyl, C<sub>4-14</sub> cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X<sup>1</sup> and X<sup>2</sup>, independently, is O or S;

Y<sup>1</sup> is -CH<sub>2</sub>-, -S-, -N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-,

-O-C(O)-O-, or a bond; each of R<sup>a</sup> and R<sup>b</sup>, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y<sup>2</sup> is -CH<sub>2</sub>;

L is an unsaturated a-straight C<sub>3-6</sub> C<sub>4-6</sub> hydrocarbon chain containing at least one double bond adjacent to Y<sup>2</sup>; said unsaturated hydrocarbon chain being substituted with C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, amino, nitro, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub> alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-O-, -O-C(O)-N(R<sup>c</sup>)-, -N(R<sup>c</sup>)-C(O)-

$N(R^d)$ -, or  $-O-C(O)-O-$ ; each of  $R^c$  and  $R^d$ , independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;  
provided that when  $L$  is  $C_4$ ,  $A$  is  $C_{3-14}$  cycloalkyl then  $Y_+$  is not  $CH_2$ ; and further provided that when  $L$  is  $C_4$  containing two double bonds, and is  $\omega$  substituted with phenyl or substituted phenyl,  $A$  is not phenyl or substituted phenyl; further provided that when  $L$  is  $C_{3-7}C_{4-6}$  and contains one triple bond or one or two double bonds and  $A$  is phenyl or substituted phenyl,  $Y^+$  is not a bond or  $-CH_2-$ , and  $Y^2$  is  $-CH_2-$  or a salt thereof, wherein the compound is not 5, 5-diphenylpent-4-enoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-tridecenoic acid.

92. (Previously Presented) The compound of claim 91, wherein  $X^1$  is O.

93. (Previously Presented) The compound of claim 91, wherein  $X^2$  is O.

94. (Previously Presented) The compound of claim 91, wherein each of  $X^1$  and  $X^2$  is O.

95. (Canceled)

96. (Currently Amended) The compound of claim 91, wherein  $L$  is an unsaturated  $C_{4-6}$  hydrocarbon chain containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being substituted with  $C_{1-2}$  alkoxy,  $-NH_2$ ,  $-NH(C_{1-2}$  alkyl),  $-N(C_{1-2}$  alkyl) $_2$ ,  $-N(C_{1-2}$  alkyl) $_2$ , halo, or monocyclic aryl.

97. (Previously Presented) The compound of claim 96, wherein said double bond is in trans configuration.


98. (Canceled)

99. (Previously Presented) The compound of claim 91, wherein A is phenyl optionally substituted with alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl, or amino.

100. **(Previously Presented)** The compound of claim 91, wherein L is an unsaturated C<sub>5-6</sub> hydrocarbon chain containing double bonds only in trans configuration, said unsaturated hydrocarbon chain being substituted with C<sub>1-2</sub> alkoxy, -NH<sub>2</sub>, -NH(C<sub>1-2</sub> alkyl), -N(C<sub>1-2</sub> alkyl)<sub>2</sub>, halo, or monocyclic aryl.

101. **(Previously Presented)** The compound of claim 100, wherein X<sup>1</sup> is O; X<sup>2</sup> is O; and Y<sup>1</sup> is -CH<sub>2</sub>-, -N(R<sup>a</sup>)-, or a bond.

102. **(Currently Amended)** A compound of formula (I):



wherein

A is a cyclic moiety selected from the group consisting of C<sub>3-14</sub> cycloalkyl, 3-14 membered heterocycloalkyl, C<sub>4-14</sub> cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, a heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X<sup>1</sup> and X<sup>2</sup>, independently, is O or S;

Y<sup>1</sup> is -CH<sub>2</sub>-, -O-, -S-, -N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-, -O-C(O)-O-, or a bond; each of R<sup>a</sup> and R<sup>b</sup>, independently being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;


Y<sup>2</sup> is CH<sub>2</sub>;

L is an unsaturated a straight C<sub>3-7</sub> C<sub>4-7</sub> hydrocarbon chain optionally containing at least one double bond adjacent to Y<sup>1</sup> or Y<sup>2</sup>; said unsaturated-hydrocarbon chain being optionally substituted with C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, nitro, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub>

alkylcarbonyloxy,  $C_{1-4}$  alkylcarbonyl, or formyl; and further being optionally interrupted by  $-O-$ ,  $-N(R^e)-$ ,  $-N(R^e)-C(O)-O-$ ,  $-O-C(O)-N(R^e)-$ , or  $-O-C(O)-O-$ ; each of  $R^e$  and  $R^d$ , independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; that when L contains three double bonds, said hydrocarbon chain is further substituted with  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  alkoxy, hydroxyl, halo, amino, nitro,  $C_{3-8}$  cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl,  $C_{1-4}$  alkylcarbonyloxy,  $C_{1-4}$  alkylcarbonyl, or formyl; and further provided that when L is  $C_4$  or  $C_5-C_{3-7}C_{4-7}$  and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl,  $Y^+$  is not a bond or  $-CH_2-$ , and  $Y^2$  is  $-CH_2-$ ; provided that when L is  $C_4$ , A is  $C_{3-4}$  cycloalkyl then  $Y^+$  is not  $CH_2$ ; and further provided that when L is  $C_4$  containing two double bonds, and is  $\omega$  substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, or 5, 5-diphenylpent-4-enoic acid.

103. (Currently Amended) A compound of formula (I):



wherein

A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl;  
each of  $X^1$  and  $X^2$ , independently, is O or S;  
 $Y^1$  is  $-CH_2-$ ,  $-S-$ ,  $-N(R^a)-C(O)-O-$ ,  $-O-C(O)-N(R^a)-$ ,  $-N(R^a)-C(O)-N(R^b)-$ ,  $-O-C(O)-O-$ , or a bond; each of  $R^a$  and  $R^b$ , independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;  
 $Y^2$  is  $-CH_2-$ ;

L is an unsaturated a straight  $C_{3-6} C_{4-6}$  hydrocarbon chain containing at least one double bond

adjacent to  $Y^1$  or  $Y^2$ ; said unsaturated hydrocarbon chain being substituted with  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  alkoxy, amino, nitro,  $C_{3-5}$  cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl,  $C_{1-4}$  alkylcarbonyloxy,  $C_{1-4}$  alkyloxycarbonyl,  $C_{1-4}$  alkylcarbonyl, or formyl; and further being optionally interrupted by  $O$ ,  $N(R^e)$ ,  $N(R^e)C(O)O$ ,  $O-C(O)-$ ,  $N(R^e)-N(R^e)C(O)-N(R^d)$ , or  $O-C(O)-O$ ; each of  $R^e$  and  $R^d$ , independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; provided that when  $L$  is  $C_4$ ,  $A$  is  $C_{3-14}$  cycloalkyl then  $Y_+$  is not  $CH_2$ ; and further provided that when  $L$  is  $C_4$  containing two double bonds, and is  $\omega$  substituted with phenyl or substituted phenyl,  $A$  is not phenyl or substituted phenyl; further provided that when  $L$  is  $C_{3-7}$  and contains one triple bond or one or two double bonds and  $A$  is phenyl or substituted phenyl,  $Y^+$  is not a bond or  $CH_2$ , and  $Y^2$  is  $CH_2$ ; or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid or 5, 5-diphenylpent-4-enoic acid.